FDA Approves Enfortumab Vedotin for Metastatic or Advanced Urothelial Cancer

The FDA granted accelerated approval to enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial cancer.

Read the full article here

Related Articles